Hepatitis C Virus (HCV) Antibody Verification

CPT: 86804
Print Share

Test Details


Since as many as 90% of commercial intravenous immunoglobulins test positive for hepatitis C antibody, an artifactual positive can result briefly after transfusion. Following the development of sensitive and specific testing for hepatitis B, 90% of post-transfusion hepatitis is now hepatitis C. A gene product (c100) of hepatitis C virus (HCV) was isolated and an assay for anti-HCV developed. The assay detects antibody to presumptive togavirus, which may be an etiologic agent of non-A, non-B hepatitis (which may not be a unitary disease entity).


Testing for HCV antibodies is to assess past or present exposure to hepatitis C virus infection; additional testing for the hepatitis virus is required to determine acute or active infection.


Electrochemiluminescence (ECLIA)

Specimen Requirements


Serum or plasma


1 mL

Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)


Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube


If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.

Storage Instructions


Stability Requirements



Room temperature

4 days


14 days


14 days

Causes for Rejection

Non-EDTA plasma specimen; PST gel-barrier tube

Clinical Information

Special Instructions

This assay is offered to provide verification of a positive HCV antibody screen obtained using the Siemens Advia Centaur HCV assay or other reagent with comparable sensitivity and specificity. Because the verification methodology is Roche ECLIA, this assay cannot be used to verify an initial screen performed with the Roche methodology.

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.


Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902):359-362. 2523562
Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology., 1997; 26(3 Suppl 1):34S-38S.9305661
Hepatitis C past and present. 2011 Case Definition. CDC CSTE Case Definition, Number 10-ID-09.
Koff RS, Dienstage JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis. 1995; 15(1):101-109.7597440
Roche Anti-HCV. Package insert 2011-01.


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
144090 HCV Antibody Verification 13955-0 144091 HCV Antibody Verification 13955-0

For Providers

Please login to order a test.


© 2018  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf